1-11 of 11
carfilzomib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Luciano J. Costa, Faith E. Davies, Gregory P. Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Jonathan L. Kaufman, Wan-Jen Hong, Monique Dail, Ahmed Hamed Salem, Xiaoqing Yang, Abdullah A. Masud, Wijith Munasinghe, Jeremy A. Ross, Orlando F. Bueno, Shaji K. Kumar, Edward A. Stadtmauer
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3748–3759.
https://doi.org/10.1182/bloodadvances.2020004146
Published: 2021
Includes: Supplemental data
Journal Articles

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

Eva De Smedt, Julie Devin, Catharina Muylaert, Nicolas Robert, Guilhem Requirand, Philip Vlummens, Laure Vincent, Guillaume Cartron, Ken Maes, Jerome Moreaux, Elke De Bruyne
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2325–2338.
https://doi.org/10.1182/bloodadvances.2020003217
Published: 2021
Includes: Supplemental data
Journal Articles

Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death

Debora Soncini, Paola Minetto, Claudia Martinuzzi, Pamela Becherini, Valeria Fenu, Fabio Guolo, Katia Todoerti, Giovanni Calice, Paola Contini, Maurizio Miglino, Giulia Rivoli, Sara Aquino, Alida Dominietto, Antonia Cagnetta, Mario Passalacqua, Santina Bruzzone, Alessio Nencioni, Massimo Zucchetti, Tommaso Ceruti, Antonino Neri, Roberto M. Lemoli, Michele Cea
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4312–4326.
https://doi.org/10.1182/bloodadvances.2020001639
Published: 2020
Includes: Supplemental data
Journal Articles

Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events

Clinical Trials & Observations
Yoshiaki Abe, Tetsuya Kobayashi, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Daisuke Miura, Masami Takeuchi, Kosei Matsue
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1725–1728.
https://doi.org/10.1182/bloodadvances.2019000247
Published: 2019
Includes: Supplemental data
Journal Articles

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma

Kyle Runckel, Matthew J. Barth, Cory Mavis, Juan J. Gu, Francisco J. Hernandez-Ilizaliturri
Journal: Blood Advances
Blood Adv (2018) 2 (23): 3516–3525.
https://doi.org/10.1182/bloodadvances.2018018168
Published: 2018
Includes: Supplemental data
Journal Articles

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion

Clinical Trials & Observations
Andrew Jay Portuguese, Brea Lipe
Journal: Blood Advances
Blood Adv (2018) 2 (23): 3443–3446.
https://doi.org/10.1182/bloodadvances.2018027532
Published: 2018
Journal Articles

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

Sondra Downey-Kopyscinski, Ellen W. Daily, Marc Gautier, Ananta Bhatt, Bogdan I. Florea, Constantine S. Mitsiades, Paul G. Richardson, Christoph Driessen, Herman S. Overkleeft, Alexei F. Kisselev
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2443–2451.
https://doi.org/10.1182/bloodadvances.2018016360
Published: 2018
Includes: Supplemental data
Journal Articles

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

Clinical Trials & Observations
Ajai Chari, A. Keith Stewart, Stuart D. Russell, Philippe Moreau, Joerg Herrmann, Jose Banchs, Roman Hajek, John Groarke, Alexander R. Lyon, George N. Batty, Sunhee Ro, Mei Huang, Karim S. Iskander, Daniel Lenihan
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1633–1644.
https://doi.org/10.1182/bloodadvances.2017015545
Published: 2018
Includes: Supplemental data
Journal Articles

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma

Clinical Trials & Observations
Ajai Chari, Hearn J. Cho, Amishi Dhadwal, Gillian Morgan, Lisa La, Katarzyna Zarychta, Donna Catamero, Erika Florendo, Nadege Stevens, Daniel Verina, Elaine Chan, Violetta Leshchenko, Alessandro Laganà, Deepak Perumal, Anna Huo-Chang Mei, Kaity Tung, Jami Fukui, Sundar Jagannath, Samir Parekh
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1575–1583.
https://doi.org/10.1182/bloodadvances.2017007427
Published: 2017
Includes: Supplemental data
Journal Articles

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Erasmia Psimenou, Dimitrios Ziogas, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Ioannis Panagiotidis, Argyrios Ntalianis, Elektra Papadopoulou, Kimon Stamatelopoulos, Efstathios Manios, Constantinos Pamboukas, Sofoklis Kontogiannis, Evangelos Terpos, Efstathios Kastritis
Journal: Blood Advances
Blood Adv (2017) 1 (7): 449–454.
https://doi.org/10.1182/bloodadvances.2016003269
Published: 2017
Journal Articles

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

Clinical Trials & Observations
Luciano J. Costa, Ilene K. Brill, James Omel, Kelly Godby, Shaji K. Kumar, Elizabeth E. Brown
Journal: Blood Advances
Blood Adv (2017) 1 (4): 282–287.
https://doi.org/10.1182/bloodadvances.2016002493
Published: 2017
Includes: Supplemental data